Recursion Pharmaceuticals Inc
NASDAQ:RXRX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.7
15.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RXRX stock under the Base Case scenario is 1.89 USD. Compared to the current market price of 6.03 USD, Recursion Pharmaceuticals Inc is Overvalued by 69%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Recursion Pharmaceuticals Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
Valuation History
Historical valuation for RXRX cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Recursion Pharmaceuticals Inc
Balance Sheet Decomposition
Recursion Pharmaceuticals Inc
Current Assets | 474.2m |
Cash & Short-Term Investments | 427.6m |
Receivables | 2.3m |
Other Current Assets | 44.3m |
Non-Current Assets | 252.3m |
PP&E | 159.2m |
Intangibles | 86.1m |
Other Non-Current Assets | 7m |
Current Liabilities | 108.9m |
Accounts Payable | 2.3m |
Accrued Liabilities | 48.8m |
Other Current Liabilities | 57.8m |
Non-Current Liabilities | 93.1m |
Long-Term Debt | 20.5m |
Other Non-Current Liabilities | 72.5m |
Earnings Waterfall
Recursion Pharmaceuticals Inc
Revenue
|
65.2m
USD
|
Cost of Revenue
|
-42.3m
USD
|
Gross Profit
|
22.9m
USD
|
Operating Expenses
|
-417m
USD
|
Operating Income
|
-394.2m
USD
|
Other Expenses
|
16.4m
USD
|
Net Income
|
-377.8m
USD
|
Free Cash Flow Analysis
Recursion Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
RXRX Profitability Score
Profitability Due Diligence
Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
RXRX Solvency Score
Solvency Due Diligence
Recursion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Recursion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXRX Price Targets Summary
Recursion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RXRX is 10.05 USD with a low forecast of 6.06 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for RXRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RXRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
The intrinsic value of one RXRX stock under the Base Case scenario is 1.89 USD.
Compared to the current market price of 6.03 USD, Recursion Pharmaceuticals Inc is Overvalued by 69%.